Soleno Therapeutics/$SLNO

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Soleno Therapeutics

Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.

Ticker

$SLNO
Sector
Health
Primary listing
NASDAQ

Employees

133
Headquarters
Redwood City, United States
Website
soleno.life

SLNO Metrics

BasicAdvanced
$3.1B
-
-$3.97
-2.56
-

Bulls say / Bears say

Soleno posted strong net product revenue of $31 million to $33 million in Q2 2025 from VYKAT XR, highlighting rapid market uptake for the first approved therapy for Prader-Willi hyperphagia (GlobeNewswire)
As of June 30, 2025, Soleno held about $293.8 million in cash, cash equivalents, and marketable securities, providing substantial runway to advance VYKAT XR's commercialization and ongoing R&D (GlobeNewswire)
The completion of a $200 million underwritten public offering in July 2025 signals strong institutional support and improves financial flexibility for scaling up VYKAT XR commercialization (GlobeNewswire)
Safety concerns raised by short seller Scorpion Capital cited swift reports of children being hospitalized due to possible heart failure and fluid retention, causing a 15% plunge in pre-market share price and heightening the risk of withdrawal from the market or a drop in prescriptions (Reuters)
The annual price of VYKAT XR, ranging from $466,200 to $500,000, could limit reimbursement by payers and hinder patient access in healthcare systems sensitive to cost (Reuters)
The company's $200 million public offering in July 2025, though increasing cash reserves, may dilute current shareholders and points to a dependence on external funding amid high cash burn (GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 4 Oct 2025.

SLNO News

AllArticlesVideos
Soleno Therapeutics, Inc. (SLNO) Under Investigation After Scorpion Capital Report Raises Drug Safety Concerns; Investors Urged to Contact Award-Winning Firm, Gibbs Mura

Soleno Therapeutics, Inc. (SLNO) Under Investigation After Scorpion Capital Report Raises Drug Safety Concerns; Investors Urged to Contact Award-Winning Firm, Gibbs Mura

Business Wire3 weeks ago
SLNO Investors Have Opportunity to Join Soleno Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

SLNO Investors Have Opportunity to Join Soleno Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

Business Wire3 weeks ago
Soleno reports death of patient who took genetic disorder treatment, shares fall

Soleno reports death of patient who took genetic disorder treatment, shares fall

Reuters3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $SLNO

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs